Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
Timeframe: Baseline up to Week 52
Number of Participants With Clinically Significant Changes in Physical Examinations
Timeframe: Screening up to Week 52
Number of Participants With Vital Signs of Potential Clinical Importance
Timeframe: Baseline up to Week 52
Number of Participants With Electrocardiogram (ECG) Results of Potential Clinical Importance
Timeframe: Screening up to Week 16
Number of Participants With Laboratory Test Results of Potential Clinical Importance
Timeframe: Week 1 up to Week 52
Number of Participants With Clinically Significant Changes in Neurological Examinations
Timeframe: Screening up to Week 52
Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 6
Timeframe: Baseline, Week 6
Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 16
Timeframe: Baseline, Week 16
Change From Baseline in Mini-Mental State Examination (MMSE) Score at Week 52
Timeframe: Baseline, Week 52